TrialCurveENDURE/CML-IX: reconstructed Kaplan–Meier curves
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX). Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Leukemia. 2026 Jan 12;40(2):410–7. doi: 10.1038/s41375-025-02859-1 |
|---|---|
| DOI | 10.1038/s41375-025-02859-1 |
| Registry | NCT03117816 |
| Phase | Phase 3 |
| Conditions | Chronic Myeloid Leukemia in Remission |
| Interventions | AOP2014 / Pegylated-Proline-interferon alpha-2b, Surveillance |
| Sponsor | Philipps University Marburg |
| Enrolment | 214 |
| Source licence | Figure published under CC BY 4.0 |
Molecular relapse-free survival (MRFS) — Patients with CML who discontinued TKI therapy and were randomized to ropeg-IFN maintenance or surveillance (ENDURE trial)
From figure panel · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Surveillance not reached; ropeg-IFN not reached. Survival at 18 months: Surveillance 60%; ropeg-IFN 62%. Hazard ratio Surveillance vs ropeg-IFN 1.02 (95% CI 0.68–1.54).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Surveillance | 108 | 48 | not reached |
| ropeg-IFN | 95 | 43 | not reached |
- Surveillance vs ropeg-IFN: reconstructed HR 1.02 (95% CI 0.68–1.54)
Landmark survival (reconstructed)
| Time | Surveillance | ropeg-IFN |
|---|---|---|
| 6 mo | 69.4% | 76.1% |
| 12 mo | 60.2% | 63.9% |
| 18 mo | 60.2% | 61.6% |
| 24 mo | 59.0% | 55.8% |
| 36 mo | 55.0% | 54.3% |
| 48 mo | 55.0% | 51.1% |
| 60 mo | 51.3% | 51.1% |
Checks against the published figure
- hazard ratio (direction inferred): printed 1.02, reconstructed 1.02 pass
Re-achievement of MMR (probability of a first MMR reachievement) — Patients who lost MMR and restarted TKI
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 6 months: Surveillance 91%; ropeg-IFN 83%. Hazard ratio ropeg-IFN vs Surveillance 0.79 (95% CI 0.51–1.24).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Surveillance | 45 | 45 | 3.2 |
| ropeg-IFN | 38 | 37 | 3.1 |
- ropeg-IFN vs Surveillance: reconstructed HR 0.79 (95% CI 0.51–1.24)
Cumulative incidence (reconstructed)
| Time | Surveillance | ropeg-IFN |
|---|---|---|
| 3 mo | 44.4% | 47.5% |
| 6 mo | 91.1% | 83.4% |
| 9 mo | 95.6% | 88.9% |
| 12 mo | 100.0% | 97.2% |
| 15 mo | — | 97.2% |
Checks against the published figure
- ropeg-IFN median: printed 3.1, reconstructed 3.06 pass
- Surveillance median: printed 3.2, reconstructed 3.16 pass
Re-achievement of MR4 (probability of a first MR4 reachievement) — Patients who lost MMR and restarted TKI
From figure panel · validated against the values printed on the figure · curve source: vision model
Reconstructed from the published curve. Cumulative incidence at 12 months: Surveillance 87%; ropeg-IFN 87%. Hazard ratio ropeg-IFN vs Surveillance 1.09 (95% CI 0.68–1.75).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Surveillance | 45 | 37 | 4.7 |
| ropeg-IFN | 38 | 33 | 4.1 |
- ropeg-IFN vs Surveillance: reconstructed HR 1.09 (95% CI 0.68–1.75)
Cumulative incidence (reconstructed)
| Time | Surveillance | ropeg-IFN |
|---|---|---|
| 6 mo | 57.9% | 67.3% |
| 12 mo | 86.6% | 86.9% |
| 18 mo | 93.3% | 86.9% |
| 24 mo | — | 91.3% |
Checks against the published figure
- ropeg-IFN median: printed 4.2, reconstructed 4.14 pass
- Surveillance median: printed 4.8, reconstructed 4.72 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/endure-cml-ix-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/endure-cml-ix-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Leukemia. 2026 Jan 12;40(2):410–7. doi: 10.1038/s41375-025-02859-1 doi:10.1038/s41375-025-02859-1. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/endure-cml-ix
Report a problem with these data
Related trials
- Acalabrutinib vs chlorambucil + rituximab in CLL (Asian phase 3): BICR-assessed duration of response; BICR-assessed progression-free survival; Overall survi
- PROLONG (final analysis): Overall survival; PFS after next-line treatment (randomization to second progression or de
- CLL14 (5-year update): Overall survival; Progression-free survival
- MSCs + basiliximab/CNI in steroid-resistant acute GVHD: Failure-free survival; Overall survival
- ADMYRE: Overall survival; Progression-free survival with PD confirmation by investigator's assessm
- AGILE (long-term follow-up): Overall survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials